SMPDL3B and diabetic kidney disease: As pharmacological suppression of SMPDL3b may render cells susceptible to other forms of injury and an activation of innate immunity pathways2–4, the alternative approach to utilize C1P replacement strategies may result in a safer and more effective strategy to treat DKD.